Last reviewed · How we verify
NCT06095921
The Effect of a Self-Management Program on Individuals With Scleroderma
NA trial testing Self Management Intervention Program in Scleroderma in 29 participants. Completed in 15 January 2021.
15 October 2020
Quick facts
| Lead sponsor | Emirhan Karakuş |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 15 July 2020 |
| Primary completion | 15 October 2020 |
| Estimated completion | 15 January 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Self Management Intervention Program
Conditions studied
- Scleroderma — all drugs for Scleroderma →
- Systemic Sclerosis — all drugs for Systemic Sclerosis →
Sponsor
Emirhan Karakuş
Who can join
Adults 18 to 65, any sex, with Scleroderma or Systemic Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction: Individuals with systemic sclerosis (SSc) have problems with perceived occupational performance and satisfaction in daily life activities due to many symptoms caused by the disease. Purpose: This study will plan to examine the effect of a self-management program for individuals with SSc on perceived occupational performance and satisfaction. Materials and Methods : Twenty-nine individuals with SSC, 28 females and 1 male will participate in the study. Perceived occupational performance and satisfaction levels before and after the program will evaluate with the Canadian Ocupational Performance Measure (COPM). The training programme will design according to the activities of COPM, the needs of the patients, and the literature. The programme consists of 8 sessions for 8 weeks, 1 day a week for 45 minutes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The effect of self-management program performed via telerehabilitation on occupational performance and satisfaction of individuals with systemic sclerosis.
Karakuş E, Sari F, Avanoğlu Güler A, Oskay D, et al · · 2025 · PMID 40343156 · DOI 10.1177/03080226241283288
Verify or expand the search:
- PubMed search for NCT06095921
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Scleroderma
Currently open trials in the same condition.
- NCT07292961 — Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed Wi · NA · recruiting
- NCT06801119 — Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） · Phase 1 · recruiting
- NCT06554132 — Respiratory Muscle Strength and Aerobic Capacity in Scleroderma · recruiting
- NCT03800017 — Skeletal Muscle Function in Interstitial Lung Disease · NA · recruiting
- NCT06598982 — Investigation of Respiratory Muscle Sarcopenia in Patients With Systemic Sclerosis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06095921 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emirhan Karakuş
- Last refreshed: 23 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06095921.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing